No Data
Growth 250 has risen for four consecutive days, and there has been a Sell on Gloving, according to Emerging Markets on the 15th.
The Tokyo Stock Exchange Growth Market 250 Index has risen for four consecutive days. Following the rise in US stocks, broad buying has continued in Emerging Markets. Sanbio <4592.T>, Synspective <290A.T>, and BASE <4477.T> have all seen increases. ABJA <5574.T>, which raised its performance forecast, temporarily hit the upper limit, but Globing <277A.T>, which also raised its forecast, faced selling pressure. In the Standard Market, Jay Holdings <2721.T> saw a significant rise.
TIMs, BASE, and others [Emerging Markets press release]
The acquisition of self-owned shares for <3645> Medical Net has ended. The acquisition of self-owned shares for <4477> BASE has ended. The results of the Phase I clinical trial for TIM's TMS-008.
BASE: Extraordinary Report
BASE: Confirmation
BASE: Securities Report - 12th Term (2024/01/01 - 2024/12/31)
Growth 250 has risen for five consecutive days, with Timy and others also increasing = Emerging Markets, 21st.
The Tokyo Stock Exchange Growth Market 250 Index has risen for five consecutive days. In the market over the weekend, it showed a slight decline in the later session while the Nikkei average fell into negative territory, but managed to stay in the positive zone. Companies such as Timee <215A.T>, SanBio <4592.T>, and Heartseed <219A.T> saw increases. BASE <4477.T> and Trial Holdings <141A.T> experienced selling pressure. The IPO of Meek <332A.T> started with a slight gain. Provided by Wealth Advisor Company.